

## Special Issue

# Vaccine Candidate against SARS-CoV-2

### Message from the Guest Editors

The quest for a vaccine against SARS-CoV-2 has mobilized a multitude of researchers worldwide that combined their expertise and effort for the rapid development of effective products. In this special issues, we want to highlight:

- the vaccine platforms already available before the COVID-19 pandemic, which have been quickly scaled-up to develop vaccines against SARS-CoV-2
- aspects related to the immunogenicity, safety and efficacy of licensed vaccines, including the durability of immune responses and the protection against variants
- new generations of vaccines/new vaccine candidates against COVID-19
- strategies to improve the efficacy of COVID-19 vaccination
- vaccination strategies for particular populations (e.g. children, the elderly, fragile subjects)
- immunological correlate of protection

Original research articles and short communications on pre-clinical and clinical studies are welcome, as well as reviews and commentaries.

---

### Guest Editors

Prof. Dr. Antonella Caputo

Department of Chemical, Pharmacological and Agricultural Sciences,  
University of Ferrara, 44121 Ferrara, Italy

Dr. Francesco Nicoli

Department of Chemical, Pharmaceutical and Agricultural Sciences,  
University of Ferrara, 44123 Ferrara, Italy

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/88548](https://mdpi.com/si/88548)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).